DiaMedica Therapeutics Inc
NASDAQ:DMAC

Watchlist Manager
DiaMedica Therapeutics Inc Logo
DiaMedica Therapeutics Inc
NASDAQ:DMAC
Watchlist
Price: 8.47 USD 1.44% Market Closed
Market Cap: 441.1m USD

Relative Value

There is not enough data to reliably calculate the relative value of DMAC.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DMAC Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.9
vs History
vs Industry
Median 3Y
-6
Median 5Y
-6
Industry
23.7
Forward
-12.1
vs History
vs Industry
Median 3Y
-6.9
Median 5Y
-6.9
Industry
22
vs History
vs Industry
Median 3Y
-6.9
Median 5Y
-6.9
Industry
24.3
vs History
1
vs Industry
22
Median 3Y
2.7
Median 5Y
2.4
Industry
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.2
vs History
vs Industry
Median 3Y
-4.2
Median 5Y
-4.1
Industry
6.1
Forward
-10.5
vs History
vs Industry
Median 3Y
-4.2
Median 5Y
-4.1
Industry
6.5
Forward
-10.9
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-4.8
Industry
7.9
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-4.8
Industry
6.3
vs History
vs Industry
2
Median 3Y
36.4
Median 5Y
28.2
Industry
5.7

Multiples Across Competitors

DMAC Competitors Multiples
DiaMedica Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
DiaMedica Therapeutics Inc
NASDAQ:DMAC
441.1m USD 0 -13.8 -11.5 -11.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 675 001.5 -160 052.3 -194 354.5 -192 136.7
US
Abbvie Inc
NYSE:ABBV
404.2B USD 6.8 172.5 16.6 23.6
US
Amgen Inc
NASDAQ:AMGN
178.1B USD 5 25.5 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
154.7B USD 5.3 19.1 12.8 12.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.2B USD 10 31.9 23.4 24.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 092 -533.8 -581.3 -565.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.2B USD 5.8 17.9 17.1 19.4
AU
CSL Ltd
ASX:CSL
83B AUD 3.6 18.5 12.5 15.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD 16.4 1 208.3 163 197.7
NL
argenx SE
XBRU:ARGX
44B EUR 14.4 33.8 58.2 59.8
P/E Multiple
Earnings Growth PEG
US
DiaMedica Therapeutics Inc
NASDAQ:DMAC
Average P/E: 190.9
Negative Multiple: -13.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 052.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
172.5
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.5
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.1
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.9
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
9%
2
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 208.3
N/A N/A
NL
argenx SE
XBRU:ARGX
33.8
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
DiaMedica Therapeutics Inc
NASDAQ:DMAC
Average EV/EBITDA: 40.3
Negative Multiple: -11.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 354.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
11%
1.6
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
163
N/A N/A
NL
argenx SE
XBRU:ARGX
58.2
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
DiaMedica Therapeutics Inc
NASDAQ:DMAC
Average EV/EBIT: 46.5
Negative Multiple: -11.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 136.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.6
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
13%
1.5
AU
CSL Ltd
ASX:CSL
15.6
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
197.7
N/A N/A
NL
argenx SE
XBRU:ARGX
59.8
N/A N/A